BRAF-targeted kinase inhibitors (KIs) are used to treat malignancies including BRAF-mutant non–small cell lung cancer, colorectal cancer, anaplastic thyroid cancer, and, most prominently, melanoma. The gene discussed is BRAF; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.